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most commonly used in clinical trial settings and to provide insight
into the extent to which outcome measures in clinical studies are
meeting payer needs. Methods: A literature review was conducted
to identify published clinical studies and ongoing/recently com-
pleted registered trials in chronic pain. Inclusion criteria were
interventional study, chronic pain in adults, and pain measured
within the primary end point. Results: Of 1256 PubMed citations and
3006 clinical trial registry entries, 356 reported large clinical studies in
pain populations (e.g., malignant, neuropathic, functional, and muscu-
loskeletal). Studies were designed for superiority in 28% of PubMed
citations and 8% of registry entries. The primary end points of most
studies were single-dimension pain instruments, such as the numer-
ical rating scale (n ¼ 131) and the visual analogue scale (n ¼ 69). In
cases in which multidimensional pain end points were used, this was
most commonly the Brief Pain Inventory (n ¼ 37). Payer-relevant endee front matter Copyright & 2015, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).
1016/j.jval.2015.07.001
est: C. E. Rycroft and R. Akehurst are full-time
national for their time conducting the literature re
yees of MundiPharma International. O. Pirk and
op@mundipharma.co.uk.
ndence to: William C.N. Dunlop, MundiPharma Int
0AB, UK.points were typically limited to secondary end points, and were limited
and/or reported inconsistently in published studies and ongoing/
recently completed studies: preference-weighted quality of life (36%
and 42%), resource use (2% and 8%), physical function (28% and 39%),
and psychological function (25% and 24%). Conclusions: Most pain
trials were not designed to show superiority to an active comparator,
and they used single-dimension pain scales as their primary end point
in combination with a broader selection of secondary end points.
The inclusion of payer-relevant end points among clinical trials was
inconsistent.
Keywords: chronic pain, end points, health technology assessment,
literature review.
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Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The burden of chronic pain includes a quality-of-life impact for
individual patients and an economic impact on society. For
patients, chronic pain interferes with sleep, employment, and
everyday activities and is frequently associated with depression
[1]. For society, chronic pain has a direct impact on health care
resource use and an indirect economic burden through missed
workdays and reduced productivity in the workplace. In Euro-
pean countries, pain is estimated to cost economies between 1%
and 10% of gross domestic product (GDP) [1]. The GDP of the
European Union (EU) was estimated to be worth €14 trillion (US
$18.5 trillion) in 2014 [2]; as such, a conservative estimate of the
burden of pain in the EU is at least €140 billion (US $185 billion).US estimates are also high; according to the Institute of Medicine,
in 2010, costs associated with pain were US $560 million to US
$630 billion [3]. In spite of this substantial burden and a large
recent investment in therapy development, there has been little
progress in developing new, efﬁcacious, and safe analgesics [4].
This limited development of new chronic pain therapies is a
multifaceted issue. Although partly due to the complexity of pain
pathways and the subjective nature of pain, research in this area
is also hindered by a lack of efﬁcacy, a potentially substantial
placebo effect, end points that are not sufﬁciently sensitive, and
the selection of end points that are not considered relevant to
payers. 'Payers' are broadly deﬁned here as those responsible for
ﬁnancing or reimbursing health care services and health tech-
nology assessment bodies. This situation is reﬂected in a recentociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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in which it calls for new diagnostic measures and improved
clinical research methods to determine the efﬁcacy of pain treat-
ments [3].
To justify any increased expenditure over existing standards
of care, in pain, as in any therapeutic area, a payer-relevant
patient beneﬁt must be demonstrated to result from the use of
the new treatment. Often, this requires the demonstration of
superiority on primary and secondary end points in relevant
trials. In some circumstances, however, payers may accept
demonstration of other beneﬁts in terms of improvements in
speciﬁc, but often subjective, patient-related end points within
the context of a noninferiority study. Which payer-relevant end
points are accepted may differ by jurisdiction but frequently
include efﬁcacy (e.g., reduction in pain), preference-weighted
quality of life (e.g., EuroQol ﬁve-dimensional (EQ-5D) question-
naire, short-form 36 health survey, or a measure that can be
mapped to the EQ-5D questionnaire, especially in markets requir-
ing cost-utility analyses), patient function (e.g., physical function,
psychological function, and, in some markets, work impairment),
and/or resource use (e.g., hospitalization and physician visits)
[5–11].
To consider the need, design, and application of de novo
outcome measures, or to create suitable combinations of existing
outcome measures for the assessment of pain, it is essential to
ﬁrst identify the types and frequency of the measures currently
used in trials of pain therapies. The present study identiﬁed these
measures by means of a structured and comprehensive literature
review of published and ongoing/recently completed clinical
trials in chronic pain and reported the type of end points
included within each study design. By grouping the end points
into broad domains that may be of interest to payers, we
attempted to understand the extent to which the use of end
points in clinical studies may be meeting the needs of payers. In
documenting how clinical studies are currently designed, how
researchers are attempting to demonstrate the value of their
products, and how payer-relevant end points are used, this
research aimed to inform efforts to improve value demonstration
in pain trials and thus to help improve patient access to novel
pain treatments.Methods
A structured, comprehensive literature review of published
clinical studies in PubMed and of ongoing/recently completed
registered trials in clinical trial registries was conducted
to identify clinical studies in areas of chronic pain, which could
be malignant, neuropathic, functional, or musculoskeletal in
origin.
PubMed Searches for Published Clinical Studies
For searching PubMed, terms were selected using Medical Subject
Headings (MeSH) in the ﬁrst instance. MeSH terms were identiﬁed
for the general areas of chronic pain (e.g., malignant, neuro-
pathic, functional, and musculoskeletal), instruments to assess
pain, quality of life, and clinical studies (randomized controlled
trials [RCTs] and non-RCT studies). Once suitable MeSH terms
were identiﬁed for these areas, each MeSH term was investigated
to identify the entry terms that were associated with each. As
such, a combination of MeSH terms and text words was used to
identify relevant articles.
The searches were limited to human studies. Comments,
letters, news articles, editorials, case reports, preclinical studies,
in vitro studies, review articles, and studies in children were
excluded.The searches were limited to English-language articles only.
To restrict the literature review to the most recent studies in
pain, and to keep the search results manageable, the search for
RCTs was limited to articles published from 2009 onward (i.e.,
approximately 5 years). Because the search for non-RCTs was
considered supplementary to the RCT search, the search was
limited to articles published from 2012 onward (i.e., approxi-
mately 2 years). The full search strategy used to search PubMed is
presented in Appendix A in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.07.001. The search in PubMed
was conducted on April 24, 2014.Trial Registry Searches for Ongoing/Recently Completed
Clinical Trials
Three clinical trial registries were searched: ClinicalTrials.gov: http://clinicaltrials.gov
 World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP): http://apps.who.int/trialsearch/
 EU Clinical Trials Register: https://www.clinicaltrialsregister.
eu
Using the terms identiﬁed for the PubMed searches already
described, a search strategy was devised for the clinical trial
registries using a combination of terms for chronic pain, for
instruments, and for quality of life. MeSH terms are not available
for the trial registries; therefore, only a combination of text words
and ﬁlters was applied. In addition, the search facilities in
the registries are not as sophisticated or do not allow the
same search string length as in PubMed; thus, it was not possible
to use all the same search terms. As such, the primary
search terms were used as a basis to create search strategies
for the registries.
The search strategy required slight modiﬁcations for each
registry to allow for the differences in search capabilities between
the registries. These search strategies are presented in Appendix
A in Supplemental Materials (see Appendix Table 2 for Clinical-
Trials.gov, Appendix Table 3 for WHO ICTRP, and Appendix
Table 4 for the EU Clinical Trials Register). The searches were
conducted on March 17, 2014 (ClinicalTrials.gov), March 31, 2014
(WHO ICTRP), and April 3, 2014 (EU Clinical Trials Register).Screening of Articles and Trial Entries
Titles and abstracts of identiﬁed citations from PubMed and the
list of relevant clinical trials from registers were screened for
relevance by one researcher against prespeciﬁed inclusion/exclu-
sion criteria (Table 1). In particular, strict screening criteria were
used in relation to the population to manage the volume of
literature in this widely researched therapy area. Speciﬁcally,
studies in children were excluded because the focus of this
review was pain in adults; studies in acute pain were excluded
because this review is focused on long-term chronic pain con-
ditions; studies in healthy volunteers were excluded because this
review is focused on the treatment of pain in patients with the
condition; and studies conducted in fewer than 100 patients were
excluded to focus on the larger, more robust studies.
For the articles from PubMed, in cases in which a decision
could not be reached on the basis of the abstract, the full-text
article was retrieved and reviewed by one researcher against the
same inclusion/exclusion criteria. If a decision could still not be
reached, a second researcher reviewed the full-text article, and
the reviewers discussed their observations to reach a consensus.
The inclusion and exclusion processes were recorded, including
the completion of a Preferred Reporting Items for Systematic
Table 1 – Inclusion/exclusion criteria.
Inclusion criteria Exclusion criteria
Population Population
 Adults with chronic pain (e.g.,
malignant, neuropathic, functional,
and musculoskeletal)
 Children
 Acute pain
 Healthy volunteers
 o100 patients
Study design Study design
 Interventional studies
 Randomized controlled
trials (RCTs)
 Prospective non-RCTs (for
results from PubMed, published
in 2012 onward)
 Prospective observational
studies (for results from
PubMed, published in 2012
onward)
 Validation/pilot studies (for
results from PubMed, published
in 2012 onward)
 In addition, results from clinical
trial registers
 Ongoing, recruiting, or
completed in 2012 onward
 Phase 3 or phase 4 studies
 Noninterventional
 Reviews
 In vitro studies
 Preclinical studies
 Comments
 Letters
 Editorials
 Case reports
 In addition, results from
clinical trial registers
 Suspended/
terminated/
withdrawn
 Completed
before 2012
 Phase 1 and phase 2
studies
Outcomes
 Pain measured within the primary
end point, using either of the
following
 Instruments measuring pain
 Quality-of-life measures
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searches and the searches in trial registries [12].
Data Extraction and Analysis
Data were extracted from all identiﬁed publications and regis-
tered trials focusing on the following information:1. Indication (and overall type of indication: all chronic, malig-
nant, neuropathic, functional, musculoskeletal, operative
[peri- or postoperative] pain).2. Intervention (and type of intervention: pharmaceutical, device,
surgery, physiotherapy, psychoeducation, multidisciplinary).3. Comparator.
4. Primary end point and its design (i.e., whether primary,
coprimary, or composite).
5. Measurement instrument used for the primary end point.
6. Secondary end point(s) and core outcome domains under which
these ﬁt (i.e., single-dimension pain scale, multidimensional pain
scales [i.e., measuring more than one dimension, typically inten-
sity], multidimensional neuropathic pain scales, pain frequency/
duration, speed/ease of analgesia, physical function [e.g., dis-
ability], psychological function [e.g., depression and anxiety],
sleep, speciﬁc adverse event measures, preference-weighted
quality-of-life measures, global impressions of change, patient
satisfaction, discontinuations, analgesic medication use, and
resource use). These core outcome domains have been largely
based on the core outcome measures recommended by
IMMPACT for clinical trials of chronic pain treatments [13],
supplemented by outcomes of interest to payers (e.g., resource
use and preference-weighted quality of life).7. Study type.
8. Superiority/noninferiority study.
Data were analyzed to identify patterns and trends in end
point selection, in terms of combinations of primary and secon-
dary end points used, and were analyzed by indication and/or
intervention. For reporting end points, each incidence of an end
point was reported for each trial; there were multiple end points
reported for each trial because the aim was to look at the
frequency of use of these measures.Results
Overview of the Clinical Trials
Figure 1 presents Preferred Reporting Items for Systematic
Reviews and Meta-Analyses ﬂow diagrams showing the inclu-
sion/exclusion processes for identifying published studies (A) and
clinical trials from the registries (B). The list of all included
studies is provided in Appendix B in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.07.001.
The analysis of clinical trials provides a picture of the practice
in published and ongoing/recently completed trials. Of the 356
studies included, 132 were published clinical trials and 224 were
ongoing/recently completed trials from the registries. Musculos-
keletal pain and neuropathic pain made up 35% and 27%,
respectively, of the published trials. For the ongoing/recently
completed studies, 41% of the studies were for neuropathic pain,
while only 16% were for musculoskeletal pain. Malignant pain
was the other major category, making up 23% of the published
studies and 24% of the ongoing/recently completed trials. The
proportion of trials investigating pharmaceutical therapies was
65% of the published trials and 83% of the ongoing/recently
completed trials.
Study Comparator and Design
The number of studies that have a placebo control, an active
control with noninferiority design, and an active comparator with
a superiority design was determined. Analysis of the trials does
not show superiority designs to be very common in either the
recent past or current practice. Approximately 67% of published
trials and 58% of ongoing/recently completed trials did not have
an active comparator. In addition, for 25% of the ongoing/recently
completed trials, the design could not be identiﬁed from the
information provided in the registry entries. For the published
studies, of the remaining 33% that did have an active comparator,
84% were designed for superiority, with the rest having non-
inferiority designs. For the ongoing/recently completed trials, of
the remaining 17% that did have an active comparator, 46% were
designed as superiority studies, while the remainder were of a
noninferiority design.
Primary End Points
Most of the trials identiﬁed a single variable as a primary end
point (n ¼ 310), of which most were single-dimension pain end
points, most commonly a numerical rating scale (NRS; n ¼ 131)
and a visual analogue scale (VAS; n ¼ 69). Where multidimen-
sional pain scales were used, this was most commonly the Brief
Pain Inventory (n ¼ 37). Further details on these three commonly
used pain scales are as follows:1. The NRS is a segmented 11-point numeric scale in which a
respondent selects a whole number (0–10), usually on a
horizontal bar or line, that best reﬂects the intensity of pain
[14]. The NRS is also anchored by terms describing pain
Fig. 1 – PRISMA diagrams of the inclusion/exclusion process of literature review. (A) Articles from PubMed. (B) Records from
clinical trial registries. EU, European Union; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses;
WHO ICTRP, World Health Organization International Clinical Trials Registry Platform.
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“no pain”) and 10 representing the other pain extreme (e.g.,
“pain as bad as you can imagine” or “worst pain imaginable”).2. The VAS is a continuous scale composed of a line, usually 100
mm in length, anchored by two verbal descriptors, one for “no
pain” (score of 0) and one for “pain as bad as it could be” or
“worst imaginable pain” (score of 100) [14]. The patients are
asked to rate their own pain on the line.3. The Brief Pain Inventory is a multidimensional pain scale that
can be self-administered or clinician administered, depending
on the patient [15]. It consists of a pain intensity scale (0–10
numeric scale), a pain interference scale (assesses the extent to
which pain interferes with patient function on a 0 to 10 numeric
scale [i.e., mood, physical activity, work, social activity, relation-
ships, and sleep]), and questions on pain relief, pain quality,
and patient perception about the cause of pain [15].
The NRS was commonly used in ongoing/recently completed
trials (46% [n ¼ 87]) and in published trials (37% [n ¼ 44]), whereas
the VAS was used to a lesser extent in published studies (29% [n ¼
34]) and ongoing/recently completed trials (18% [n ¼ 35]). Where
primary end points measured multiple variables, they often
combined a single-dimension pain scale with speciﬁc measures
of tolerability (e.g., severity of adverse events or discontinuations),
measures of function, or amount of medication used.
Domains of Measurement—Primary and Secondary
Core outcome domains have been analyzed within the published
and ongoing/recently completed trials. Figure 2 shows the pro-
portion of studies taking a measurement (either primary or
secondary) in each of the outcome domains.
For domains identiﬁed as speciﬁcally of interest to payers in
published and ongoing/recently completed studies, the following
frequencies were observed:. 2 – Domains of measurement (primary and secondary) used
s reported for each trial; therefore, there were multiple outco1.by
mePreference-weighted quality-of-life measures (e.g., short-form
36 health survey and EQ-5D questionnaire) are used in fewer
than 50% of the trials (published [P] 42%; ongoing/recently
completed [O] 36%). When considering superiority studies
alone (data not shown in Fig. 2), 39% assessed preference-
weighted quality of life (P 35%; O 47%).2. Fewer than 10% of the studies assessed resource use (P 8%; O
2%). When considering superiority studies alone (data not
shown in Fig. 2), 9% assessed resource use (P 5%; O 17%).3. There is limited and inconsistent use of end points for
measuring patient function, including physical function (P
39%; O 28%) and psychological function (P 24%; O 25%). When
considering superiority studies alone (data not shown in
Fig. 2), 48% assessed physical function (P 54%; O 35%) and
33% assessed psychological function (P 30%; O 41%).
To further investigate the reporting of these domains, the studies
were analyzed by the proportion of studies in each general indica-
tion taking a measurement in each core outcome domain (Fig. 3).
When considering both published and ongoing/recently completed
studies together, studies in musculoskeletal and functional pain
have been more likely than studies in other indications to measure
the payer-relevant end points such as quality of life, patient
function, and resource use. When comparing ongoing/recently
completed studies and older published studies, however, the most
progress in terms of moving toward measurements of such payer-
relevant end points has been in the area of neuropathic pain.Discussion
To our knowledge, this is the ﬁrst literature review identifying the
key end points used in studies of interventions for alleviating
chronic pain. This literature review encompassed both publishedstudies. Note that each incidence of an outcome domain
domains reported for each trial.
Fig. 3 – The proportion of studies measuring speciﬁc outcome domains by pain type. Note that each incidence of an outcome
domain was reported for each trial; therefore, there were multiple outcome domains reported for each trial.
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review of PubMed and three large clinical trial registries, and it
focused on trials of all types of interventions, not just
pharmaceuticals.
Pain is associated with various comorbidities, and the expe-
rience of pain can affect a patient’s quality of life in many ways.
Such complexity leads to difﬁculties in clearly demonstrating
superior value of an intervention. Furthermore, studies for
pharmaceutical interventions are often designed with titration
until equal analgesic dose, which means that noninferiority on
analgesia is likely, with differentiation only in terms of adverse
effects. Assessing the main outcome domains that studies use
was of particular interest for this analysis to observe any trends
in the approaches being taken and the extent to which data of
speciﬁc relevance to payers are collected.
Although current guidelines for the design and use of end
points in pain trials demonstrate some consistency between
different regulatory agencies (i.e., the European Medicines Agency
and the Food and Drug Administration), the guidance from the
health technology assessment bodies is less clear, with most
being derived from anecdotal reporting within health technology
assessment reports of speciﬁc interventions [5–11,13,16,17]. Payer-
relevant end points differ by jurisdiction, but some or all the
markets require efﬁcacy, preference-weighted quality of life, patient
physical/psychological function, and/or resource use [5–11]. Crit-
ically, to accept higher expenditure than needed for the current
standard of care, payers require superiority in patient-related end
points, and ideally, this superiority would be demonstrated in both
primary and secondary end points.
We found that the use of end points in chronic pain trials is
dominated by a limited range of primary end points used in
combination with a wide range of secondary end points. We alsofound that only a small proportion of the identiﬁed pain studies are
designed to demonstrate superiority over an active comparator in
their primary end points. Although this approach may satisfy the
requirements of the regulatory bodies (e.g., the European Medicines
Agency recommends that the objective of trials in acute severe
nociceptive pain should be to demonstrate noninferiority to a
comparator treatment [16]), the needs of payers (i.e., those respon-
sible for paying for health care services) are often considered only
in secondary end points.
The inclusion of payer-relevant end points among clinical
trials is inconsistent. In particular, studies collecting resource use
are a rarity; the measurement of preference-weighted quality-of-
life measures, physical function, and psychological function is
more common but still limited to a minority of studies. The
situation is similar when looking at the superiority studies alone,
although the evidence suggests that this is slowly improving with
some payer-relevant end points such as preference-weighted
quality of life and resource use being included within a higher
proportion of ongoing/recently completed superiority trials com-
pared with published superiority studies.
As with all literature reviews, both the current review and the
identiﬁed data had certain limitations. First, the search was
limited to articles/records published in English; thus, relevant
articles published in another language would not have been
identiﬁed. Second, we made the following decisions at the
searching and screening stages of the literature review: for
PubMed, we restricted the searches to RCTs published within
the last 5 years (2009 onward) and to non-RCT studies published
within the last 2 years (2012 onward); we excluded phase 1 and
phase 2 clinical trials during the screening of the registry studies;
and we excluded any pilot/validation studies along with studies
involving fewer than 100 patients. This 100-patient cutoff was
V A L U E I N H E A L T H 1decided upon to allow more focus on robust trials likely to be used
in evidence to payers and to ensure that the number of literature
search results was manageable; however, it should be noted that a
large number of studies were excluded for this reason (Fig. 1). Third,
as with similar reviews involving searches of literature databases,
articles that were not indexed in PubMed would not have been
initially identiﬁed from the database searches; because no other
literature databases were searched, articles indexed in databases
other than PubMed would not have been identiﬁed. In searching the
clinical trial registries, however, we expected to identify the key
trials that have investigated or are investigating interventions for
alleviating pain. Fourth, our results suggest some potential pub-
lication bias when comparing the data from the published studies
and the ongoing/recently completed registry studies. Our ﬁnding
that 65% of the published trials investigated pharmaceutical thera-
pies compared with 83% of ongoing/recently completed trials may
indicate a trend, but it could perhaps indicate that not all pharma-
ceutical trials are being published, which must also be recognized
as a potential limitation when interpreting our ﬁndings. Finally,
although we investigated ongoing/recently completed clinical stud-
ies, and those studies that had been published, we did not
speciﬁcally compare trends in trial design/reporting over time. A
future analysis of changes over time by means of date of trial
initiation may provide results of greater depth and uncover more
exact trends over time.
The results of the present review suggest that trials measur-
ing the efﬁcacy of pain interventions have not been designed
historically to meet the needs of payers, and the use of end points
relevant to payers tends to be limited and/or inconsistent. Now
that we have a greater understanding of the end points used
within clinical trials of pain therapies, further research is
required to improve the demonstration of value in clinical studies
of pain. Three areas of further research could help to enhance the
demonstration of value in the area. First, the needs of payers
should be clearly deﬁned to help inform future studies, which can
then be designed in a manner that more closely meets payers’
needs. Second, the technical challenges of collecting payer-
relevant end points need to be reviewed. For example,
preference-weighted quality-of-life measures are not sensitive
in all disease areas and patient types; there is some evidence of
ﬂoor effects in their sensitivity for measuring the effects of pain,
which could inﬂuence the likelihood of their inclusion in clinical
trial designs. Furthermore, resource use data are particularly
difﬁcult to collect in international clinical studies with different
treatment practices across geographies, and often require a large
sample size to reach statistical signiﬁcance. Finally, the area
would beneﬁt from a more coordinated approach to approving
and valuing interventions across key stakeholders, including
payers, regulators, physicians, manufacturers, and patients.
Some of these solutions might involve prioritizing which payer-
relevant end points are critical in a clinical study, whether the
study needs to be powered for that end point, and whether the
information can be supplemented from secondary sources.Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2015.07.001 or, if a hard copy of article, at www.valueinhealth
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